National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Hepatitis B, Chronic trials

The registry lists 10 Hepatitis B, Chronic studies with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 2 6Phase 3 2Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Add-on Peginterferon Following Nucleos(t)Ide Analogue TreatmentCompletedNCT02364336Phase 2Results posted
• Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis BCompletedNCT01369212Phase 3Results posted
• Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis BTerminatedNCT01369199Phase 3Results posted
• Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis BTerminatedNCT00524173Phase 2Results posted
• Lamivudine and Adefovir to Treat Chronic Hepatitis BCompletedNCT00023309Phase 2Results posted
• VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BActive, not recruitingNCT06092333Phase 2
• Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)CompletedNCT05621304
• Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis BWithdrawnNCT03575208Phase 2
• Long-Term Lamivudine Therapy for Chronic Hepatitis BCompletedNCT00120354Phase 4
• Lamivudine for Chronic Hepatitis BCompletedNCT00001457Phase 2